LIVN LivaNova PLC

LivaNova CEO Vladimir Makatsaria discusses the company's strategic roadmap, highlighting growth in its existing cardiopulmonary and epilepsy businesses while pursuing significant opportunities in obstructive sleep apnea (OSA) and difficult-to-treat depression. The company aims to expand its neuromodulation capabilities and introduce differentiated therapies, including its investigational aura6000 system for OSA and a potential new therapy for depression awaiting CMS coverage. Makatsaria emphasizes the company's strong foundation, market leadership, and focus on addressing unmet patient needs.

Harbor Capital Advisors Inc. significantly reduced its stake in LivaNova PLC ($LIVN) by 72.3% in the third quarter, selling over 73,000 shares. Despite this, institutional ownership remains high at 97.64%, with other firms increasing or initiating positions, notably Nomura Holdings Inc. and Headlands Technologies LLC. Analysts maintain a "Moderate Buy" consensus rating for LivaNova, with recent price target upgrades from firms like Mizuho and Robert W. Baird.

Voya Investment Management LLC reduced its stake in LivaNova PLC by 17.6% (21,244 shares) during Q3, now holding 99,254 shares valued at $5.2 million. Institutional investors own about 97.64% of LivaNova, and analysts maintain a "Moderate Buy" consensus rating with an average target price of $65.63. LivaNova opened at $63.13, with a market cap of $3.45 billion and a negative P/E of -15.78, reflecting its recent performance and valuation.

KeyBanc recently initiated coverage on LivaNova (LIVN) with an Overweight rating, citing underappreciated performance, share gains, and improved clinical data. The analyst highlighted upcoming commercialization efforts for the aura6000 platform in obstructive sleep apnea and a path to better margins through leveraged growth investments. This new optimism suggests a potential reappraisal of LivaNova's growth prospects, particularly regarding aura6000 and its impact on the company's investment narrative.

LivaNova PLC announced that its CEO, Vladimir Makatsaria, and CFO, Alex Shvartsburg, will present at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026. They will participate in a fireside chat accessible via webcast. A replay will be available on the LivaNova website after the event.

LivaNova PLC (Nasdaq: LIVN), a medical technology company, announced its participation in the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. CEO Vladimir Makatsaria and CFO Alex Shvartsburg will lead a fireside chat on January 14, 2026, at 1:30 p.m. PST, accessible via webcast on the company's website. A replay of the discussion will also be available on the LivaNova website within 24 hours of the live event.